Evidence network for deaths_(OS)

1ATTRACTION-3, 20191KEYNOTE-590, 01KEYNOTE-181, 20201ESCORT, 2020camrelizumab alone vs. nivolumab alone 0.92 [0.68; 1.25]0.92 [0.68;1.25]camrelizumab alone vs. nivolumab alone 0.92 [0.68; 1.25]camrelizumab alone vs. pembrolizumab alone 0.80 [0.61; 1.05]0.80 [0.61;1.05]camrelizumab alone vs. pembrolizumab alone 0.80 [0.61; 1.05]camrelizumab alone vs. pembrolizumab plus SoC 0.97 [0.74; 1.27]0.97 [0.74;1.27]camrelizumab alone vs. pembrolizumab plus SoC 0.97 [0.74; 1.27]camrelizumab alone vs. Standard of Care (SoC) camrelizumab alone better 0.71 [0.57; 0.88]0.71 [0.57;0.88]camrelizumab alone vs. Standard of Care (SoC) camrelizumab alone better 0.71 [0.57; 0.88]nivolumab alone vs. camrelizumab alone 1.08 [0.80; 1.47]1.08 [0.80;1.47]nivolumab alone vs. camrelizumab alone 1.08 [0.80; 1.47]nivolumab alone vs. pembrolizumab alone 0.87 [0.66; 1.14]0.87 [0.66;1.14]nivolumab alone vs. pembrolizumab alone 0.87 [0.66; 1.14]nivolumab alone vs. pembrolizumab plus SoC 1.05 [0.80; 1.39]1.05 [0.80;1.39]nivolumab alone vs. pembrolizumab plus SoC 1.05 [0.80; 1.39]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.77 [0.62; 0.96]0.77 [0.62;0.96]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.77 [0.62; 0.96]pembrolizumab alone vs. camrelizumab alone 1.25 [0.96; 1.64]1.25 [0.96;1.64]pembrolizumab alone vs. camrelizumab alone 1.25 [0.96; 1.64]pembrolizumab alone vs. nivolumab alone 1.16 [0.88; 1.52]1.16 [0.88;1.52]pembrolizumab alone vs. nivolumab alone 1.16 [0.88; 1.52]pembrolizumab alone vs. pembrolizumab plus SoC 1.22 [0.96; 1.54]1.22 [0.96;1.54]pembrolizumab alone vs. pembrolizumab plus SoC 1.22 [0.96; 1.54]pembrolizumab alone vs. Standard of Care (SoC) 0.89 [0.75; 1.05]0.89 [0.75;1.05]pembrolizumab alone vs. Standard of Care (SoC) 0.89 [0.75; 1.05]pembrolizumab plus SoC vs. camrelizumab alone 1.03 [0.79; 1.34]1.03 [0.79;1.34]pembrolizumab plus SoC vs. camrelizumab alone 1.03 [0.79; 1.34]pembrolizumab plus SoC vs. nivolumab alone 0.95 [0.72; 1.25]0.95 [0.72;1.25]pembrolizumab plus SoC vs. nivolumab alone 0.95 [0.72; 1.25]pembrolizumab plus SoC vs. pembrolizumab alone 0.82 [0.65; 1.04]0.82 [0.65;1.04]pembrolizumab plus SoC vs. pembrolizumab alone 0.82 [0.65; 1.04]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.73 [0.62; 0.86]0.73 [0.62;0.86]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.73 [0.62; 0.86]Standard of Care (SoC) vs. camrelizumab alone camrelizumab alone better 1.41 [1.14; 1.74]1.41 [1.14;1.74]Standard of Care (SoC) vs. camrelizumab alone camrelizumab alone better 1.41 [1.14; 1.74]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.30 [1.04; 1.62]1.30 [1.04;1.62]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.30 [1.04; 1.62]Standard of Care (SoC) vs. pembrolizumab alone 1.12 [0.95; 1.33]1.12 [0.95;1.33]Standard of Care (SoC) vs. pembrolizumab alone 1.12 [0.95; 1.33]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.37 [1.16; 1.61]1.37 [1.16;1.61]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.37 [1.16; 1.61]placeboStandard of Care (SoC)placebo plus SoCnivolumab alonepembrolizumab plus SoCpembrolizumab alonecamrelizumab alonedirect evidencenetwork meta-analysis
T vs. C placeboStandard of Care (SoC)placebo plus SoCnivolumab alonepembrolizumab plus SoCpembrolizumab alonecamrelizumab alone
placebo---NANANANANANA
Standard of Care (SoC)NA---NA1.30
1.04; 1.62		1.37
1.16; 1.61		1.12
0.95; 1.33		1.41
1.14; 1.74
placebo plus SoCNANA---NANANANA
nivolumab aloneNA0.77
0.62; 0.96		NA---1.05
0.80; 1.39		0.87
0.66; 1.14		1.08
0.80; 1.47
pembrolizumab plus SoCNA0.73
0.62; 0.86		NA0.95
0.72; 1.25		---0.82
0.65; 1.04		1.03
0.79; 1.34
pembrolizumab aloneNA0.89
0.75; 1.05		NA1.16
0.88; 1.52		1.22
0.96; 1.54		---1.25
0.96; 1.64
camrelizumab aloneNA0.71
0.57; 0.88		NA0.92
0.68; 1.25		0.97
0.74; 1.27		0.80
0.61; 1.05		---

pathologies: 78,230,231,149,151,150,148 - treatments: 661 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons